In 2017, Abide Therapeutics, Inc. patented a series of dual lipoprotein-associatedphospholipase A2 (Lp-PLA2) and ABHD6 inhibitors for the treatmentof several pathological conditions such as multiple sclerosis, ischemia,traumatic brain injury, Alzheimer’s disease, Parkinson’sdisease, amyotrophic lateral sclerosis, cancer, and diabetes.118 These newly developed Lp-PLA2/ABHD6 inhibitorsshow the common chemical structure of 2,5-dioxoimidazolidin-1-yl phenylpiperazine-1-carboxylates,resembling N-hydroxyhydantoin 16. Here, PLA2G7 is linked to multiple sclerosis.